跳转到主要内容
搜索

策略领导力

注册

最新资源

Featured resource

Category / type

In case you missed it: CHI + Certara Webinar on Artificial Intelligence (AI) -Powered Model-Informed Drug Development (MIDD)
In case you missed it: CHI + Certara Webinar on Artificial Intelligence (AI) -Powered Model-Informed Drug Development (MIDD)Blog

In case you missed it: CHI + Certara Webinar on Artificial Intelligence (AI) -Powered Model-Informed Drug Development (MIDD)

2025 年 4 月 18 日 What’s next for drug development? Recapping our MIDD in the age of AI webinarMIDD has transformed the pharmaceutical landscape—empowering scientists and…
Protect Confidential Information in Investigational Drug Submissions
Protect Confidential Information in Investigational Drug SubmissionsBlog

Protect Confidential Information in Investigational Drug Submissions

2025 年 3 月 20 日 Health regulatory agencies require pharmaceutical companies to protect study participants’ personal information (PI) within regulatory drug submissions.…
Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study
Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding studyPublication

Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study

The IMPAACT 2017/MOCHA study, a phase 1/2 multicenter trial across five countries, assessed the safety, antiviral activity, and pharmacokinetics of…
临床试验数据的匿名化与删减处理的对比分析
Anonymization vs. Redaction of Clinical Trial DataBlog

临床试验数据的匿名化与删减处理的对比分析

2025 年 1 月 17 日 The vernacular for disclosing pharmaceutical clinical trial results to the public may seem just as confusing as…

Popular resources

Certara Launches Non-Animal Navigator™ Solution to Help Drug Developers Reduce Reliance on Animal Testing
Certara Launches Non-Animal Navigator™ Solution to Help Drug Developers Reduce Reliance on Animal TestingPress Release

Certara Launches Non-Animal Navigator™ Solution to Help Drug Developers Reduce Reliance on Animal Testing

Certara Reports Preliminary First Quarter 2025 Financial Results Announces $100 Million Share Repurchase Authorization
Certara Reports Preliminary First Quarter 2025 Financial Results Announces $100 Million Share Repurchase AuthorizationPress Release

Certara Reports Preliminary First Quarter 2025 Financial Results Announces $100 Million Share Repurchase Authorization

Introducing the new Certara.com: Transforming drug development for good, together.
Introducing the new Certara.com: Transforming drug development for good, together.Blog

Introducing the new Certara.com: Transforming drug development for good, together.

Certara & A2Healthcare accelerate Model-informed Drug Development (MIDD) adoption in Japan
Certara & A2Healthcare accelerate Model-informed Drug Development (MIDD) adoption in JapanAnnouncement

Certara & A2Healthcare accelerate Model-informed Drug Development (MIDD) adoption in Japan

Certara Enters Strategic Partnership with Biowaived to Increase Biopharmaceutics Capabilities
Certara Enters Strategic Partnership with Biowaived to Increase Biopharmaceutics CapabilitiesAnnouncement

Certara Enters Strategic Partnership with Biowaived to Increase Biopharmaceutics Capabilities

Certara Appoints Dr. Adrian McKemey as President of Drug Development Solutions
Certara Appoints Dr. Adrian McKemey as President of Drug Development SolutionsPress Release

Certara Appoints Dr. Adrian McKemey as President of Drug Development Solutions

All resources heading

订阅时事通讯

为什么订阅？因为改变药物开发不仅是我们的目标，更是我们的执着追求。如果这也是您的想法，那么请第一时间了解新见解，与我们一起推动科学发展。


沪ICP备2022021526号
Powered by Translations.com GlobalLink Web Software